Virokine Therapeutics Ltd

Virokine logo.png

Based at the London BioScience Innovation Centre in the vibrant ‘Knowledge Quarter’, and affiliates at the University of Cambridge's new Milner Institute, Virokine Therapeutics Ltd (VTL) are developing novel virus-based immunotherapy to treat infections, autoimmune disease and cancer.

VTL’s disease targeted virokine molecules are rapidly generated using a DNA discovery platform and act by modulating the chemokine system, innate conductors of active immune cell delivery, to potentiate immunisation, create new therapy and improve health.